MD3222F1 - Method of endometrial cancer diagnosis - Google Patents

Method of endometrial cancer diagnosis

Info

Publication number
MD3222F1
MD3222F1 MDA20060093A MD20060093A MD3222F1 MD 3222 F1 MD3222 F1 MD 3222F1 MD A20060093 A MDA20060093 A MD A20060093A MD 20060093 A MD20060093 A MD 20060093A MD 3222 F1 MD3222 F1 MD 3222F1
Authority
MD
Moldova
Prior art keywords
endometrial cancer
diagnosis
endometrial
cancer diagnosis
concentration
Prior art date
Application number
MDA20060093A
Other languages
Romanian (ro)
Other versions
MD3222G2 (en
Inventor
Dumitru Sofroni
Lilian GUTU
Katja Tenner
Anatolie CERNII
Mihail Todiras
Michael Bader
Original Assignee
Institutia Medico-Sanitara Publica Institutul Oncologic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institutia Medico-Sanitara Publica Institutul Oncologic filed Critical Institutia Medico-Sanitara Publica Institutul Oncologic
Priority to MDA20060093A priority Critical patent/MD3222G2/en
Publication of MD3222F1 publication Critical patent/MD3222F1/en
Publication of MD3222G2 publication Critical patent/MD3222G2/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Inventia se refera la medicina, in special la oncologie si poate fi utilizata pentru diagnosticul neinvaziv precoce si pentru confirmarea diagnosticului de cancer endometrial. Esenta inventiei constain determinarea concentratiei de ARN mesager al triptofanhidroxilazei-1 in tesuturile endometrial si miometrial, si in cazul cand in tesutul endometrial concentratia este de 2…100 ori mai mare, se stabileste diagnosticul de cancer endometrial. Rezultatul inventiei consta in posibilitatea diagnosticarii precoce diferentiate a cancerului endometrialpentru stabilirea metodei eficiente de tratament pre- si postoperator.The invention relates to medicine, especially oncology and can be used for early noninvasive diagnosis and for confirming the diagnosis of endometrial cancer. The essence of the invention consists in determining the concentration of messenger RNA of tryptophanhydroxylase-1 in the endometrial and myometrial tissues, and if in the endometrial tissue the concentration is 2 ... 100 times higher, the diagnosis of endometrial cancer is established. The result of the invention consists in the possibility of early differential diagnosis of endometrial cancer for establishing the effective method of pre- and post-operative treatment.

MDA20060093A 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis MD3222G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Publications (2)

Publication Number Publication Date
MD3222F1 true MD3222F1 (en) 2007-01-31
MD3222G2 MD3222G2 (en) 2007-08-31

Family

ID=37776647

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Country Status (1)

Country Link
MD (1) MD3222G2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3499G2 (en) * 2007-10-12 2008-09-30 Общественное Медико-Санитарное Учреждение Онкологический Институт Method of differentiated treatment of endometrial cancer
MD492Z (en) * 2011-08-17 2012-10-31 Лорена МЕДНИКОВ Method for determining the spread of intestinal type gastric cancer

Also Published As

Publication number Publication date
MD3222G2 (en) 2007-08-31

Similar Documents

Publication Publication Date Title
LTPA2016034I1 (en) Bruton tyrosine kinase inhibitors
HUP0302332A2 (en) Gene detection method for improving the likelihood of an effective response to an erbb antagoist cancer therapy
EA200900203A1 (en) ELECTORAL MODULATORS OF ANDROGENS RECEPTOR, THEIR ANALOGUES, DERIVATIVES AND APPLICATIONS
DE602005026866D1 (en) USE OF THREE-DIMENSIONAL CULTURED TISSUE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE
TN2009000292A1 (en) Formulations for cancer treatment
CO5660287A2 (en) DERIVATIVES OF TETRAHYDROCARBAZOL AND ITS PHARMACEUTICAL USE
EP2175879A4 (en) Treatment of prion protein related diseases
SE0300098D0 (en) Use of cyclin D1 inhibitors
MD3222F1 (en) Method of endometrial cancer diagnosis
SE0402507D0 (en) Medical solution, method of preparation and use thereof
DE602004019541D1 (en) CYCLOALKYLÄBÜ CONDENSED INDOLE
EA200601392A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIPODYSTROPHY
SG165413A1 (en) Pecam-1 genotype
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
IL191690A0 (en) Therapy of malignant neoplasias
MD3244F1 (en) Method of determining the endometrial cancer aggressivity
EA200801823A1 (en) STRAIN-PRODUCER OF SOLUBLE FORM OF RECOMBINANT HEPSIN PERSON (HPNTM)
CY1116592T1 (en) COGNITIVE THERAPY CONTAINING α5β1 COMPONENTS
MA37464A1 (en) Anti-egfr antibodies and their uses

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees